acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef

The American College of Cardiology's first major statement on anti-obesity medications in heart failure explicitly states that 'insufficient evidence exists to confidently conclude that semaglutide and tirzepatide reduce HF events in individuals with HFpEF and obesity' despite acknowledging improvements in symptoms and functional capacity from the STEP-HFpEF program (1,145 patients) and SUMMIT trial (731 patients). This represents institutional hedging on mortality and hospitalization endpoints even as the SUMMIT trial reported 40% reduction in HF hospitalization/mortality. The statement establishes symptom improvement as proven but maintains uncertainty on the harder clinical outcomes that determine cost-effectiveness and guideline strength. This divergence between trial-level evidence language and society-level guidance interpretation reveals how institutional medicine calibrates confidence thresholds differently than individual studies.

Relevant Notes: - GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035 - glp1-hfpef-creates-competing-mechanisms-cardiac-benefit-versus-sarcopenic-malnutrition-risk - bmi-fails-as-malnutrition-indicator-in-obese-hfpef-enabling-sarcopenic-obesity-paradox